Scholarlink

Background <p>The global obesity surge has precipitated a parallel rise in diabetes, cardiovascular, kidney, and reproductive-metabolic diseases like polycystic ovarian syndrome (PCOS), creating an unsustainable healthcare burden fragmented by organ-specific nomenclature. Legacy terms like type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) focus on end-stage manifestations, obscuring shared pathogenic roots. This review aimed to propose and define the Fuel Toxicity-Associated Spectrum (FTAS) as a unifying nomenclature and staging framework for adiposity-related metabolic disorders. This represents a novel conceptual synthesis building upon established pathophysiological principles.</p> Method <p>We conducted a narrative review, synthesizing literature on the pathophysiology and nomenclature of adiposopathy associated metabolic conditions to build a logical argument for this new mechanistic classification.</p> Review Findings <p>We propose that the FTAS framework reconceptualizes disorders from metabolic syndrome to overt organ damage as manifestations of a single pathophysiological process: chronic nutrient excess driving adipose tissue dysfunction and systemic fuel toxicity (lipotoxicity, glucotoxicity, organelle dysfunction). We provide a unifying nosology, mapping legacy diagnoses to FTAS equivalents (e.g. type 2 diabetes to FTAS-Hyperglycemia) and integrates related constructs into a hierarchical model. A novel four-stage system (Stages 0–3) was formulated, representing a hypothesis that transcending organ silos facilitates a complication-centric approach to care. The review also outlines a proposed prospective validation roadmap and a phased implementation strategy for the framework.</p> Conclusion <p>The FTAS provides a proposed holistic, pathophysiologically grounded, and destigmatizing lexicon that unifies metabolic conditions. It aligns with modern, metabolism-targeting pharmacotherapies and is hypothesized to transform clinical practice and research by promoting early, integrated intervention, though this requires prospective validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fuel toxicity-associated spectrum (FTAS): a unifying nomenclature for metabolic disorders

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月18日

查看全文
  • Pichakacheri Sureshkumar

摘要

Background

The global obesity surge has precipitated a parallel rise in diabetes, cardiovascular, kidney, and reproductive-metabolic diseases like polycystic ovarian syndrome (PCOS), creating an unsustainable healthcare burden fragmented by organ-specific nomenclature. Legacy terms like type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) focus on end-stage manifestations, obscuring shared pathogenic roots. This review aimed to propose and define the Fuel Toxicity-Associated Spectrum (FTAS) as a unifying nomenclature and staging framework for adiposity-related metabolic disorders. This represents a novel conceptual synthesis building upon established pathophysiological principles.

Method

We conducted a narrative review, synthesizing literature on the pathophysiology and nomenclature of adiposopathy associated metabolic conditions to build a logical argument for this new mechanistic classification.

Review Findings

We propose that the FTAS framework reconceptualizes disorders from metabolic syndrome to overt organ damage as manifestations of a single pathophysiological process: chronic nutrient excess driving adipose tissue dysfunction and systemic fuel toxicity (lipotoxicity, glucotoxicity, organelle dysfunction). We provide a unifying nosology, mapping legacy diagnoses to FTAS equivalents (e.g. type 2 diabetes to FTAS-Hyperglycemia) and integrates related constructs into a hierarchical model. A novel four-stage system (Stages 0–3) was formulated, representing a hypothesis that transcending organ silos facilitates a complication-centric approach to care. The review also outlines a proposed prospective validation roadmap and a phased implementation strategy for the framework.

Conclusion

The FTAS provides a proposed holistic, pathophysiologically grounded, and destigmatizing lexicon that unifies metabolic conditions. It aligns with modern, metabolism-targeting pharmacotherapies and is hypothesized to transform clinical practice and research by promoting early, integrated intervention, though this requires prospective validation.